This profile of LEA is thus intermediate in between cannabimimetic AEA [12] (which enhances feeding, body weight gain, and lipogenesis while promoting insulin resistance through the activation of cannabinoid receptors such as Cb1) and that of the non-cannabinoid NAEs OEA and POEA, two monounsaturated NAEs that reduce feeding and body weight gain; lower insulin, cholesterol, and triglycerides; and act through the activation of Ppar-α receptors [32]. The gene discussed is INS; the disease is Insulin resistance.